Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
| Autor: | Michael G. Fradley, Aarti Patel, Sachin Diwadkar |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty Heart block Case Report 030204 cardiovascular system & hematology Asymptomatic 03 medical and health sciences 0302 clinical medicine immune system diseases Internal medicine hemic and lymphatic diseases medicine cardiovascular diseases neoplasms Multiple myeloma Cardiotoxicity Bortezomib business.industry medicine.disease lcsh:RC666-701 030220 oncology & carcinogenesis Cardiology Proteasome inhibitor Mantle cell lymphoma medicine.symptom Cardiology and Cardiovascular Medicine business Atrioventricular block medicine.drug |
| Zdroj: | Case Reports in Cardiology Case Reports in Cardiology, Vol 2016 (2016) |
| ISSN: | 2090-6404 |
| Popis: | Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac complications including left ventricular dysfunction and atrioventricular block. We present the case of a 66-year-old man with multiple myeloma and persistent asymptomatic elevations of cardiac biomarkers who developed complete heart block and evidence of myocardial scar after his eighth cycle of bortezomib, requiring permanent pacemaker placement. In addition to discussing the cardiovascular complications of bortezomib therapy, we propose a potential role for biomarkers in the prediction and monitoring of bortezomib cardiotoxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text